Saturday, May 21, 2016 6:12:58 PM
More from $ONCS PR: % CRs down wrt p1. Only 9% of patients get at least 3 months of disease stabilization....mmmm, when does the p3 start?
— Juan P. Serrate, DVM (@JPZaragoza1) December 16, 2013
Also from a previous search:
https://plus.google.com/+BradLoncar/posts/8bWP3MZsyHA (see the comments section)
I'm on my way to New York. Will be at the Maidstone Cancer Immunotherapy Conference tomorrow.
— Brad Loncar (@bradloncar) March 25, 2015
$ONCS sent out a corporate advertisement via Bloomberg Businessweek. https://t.co/T86GvLYuG0
— Brad Loncar (@bradloncar) May 2, 2016
Brad Loncar manages the Loncar Immunotherapy index. If ONCS market cap were above $100M, it could have, maybe, made it on the index. Also, Brad liked Feuerstein's tweet from my previous post. I know, I have had too much free time today LOL!
But on a serious note, you are right, these prices are a gift if P2B data can hit a home run.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM